The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
|
| Abstract |
Antipsychotic polypharmacy in psychotic disorders is widespread despite international guidelines favoring monotherapy. Previous evidence indicates the utility of low-dose partial dopamine agonist (PDAs) add-ons to mitigate antipsychotic-induced metabolic adverse effects or hyperprolactinemia. However, clinicians are often concerned about using PDAs combined with high-potency, full dopaminergic antagonists (FDAs) due to the risk of psychosis relapse. We, therefore, conducted a literature review to find studies investigating the effects of combined treatment with PDAs (i.e. aripiprazole, cariprazine and brexpiprazole) and FDAs having a strong D 2 receptor binding affinity. Twenty studies examining the combination aripiprazole - high-potency FDAs were included, while no study was available on combinations with cariprazine or brexpiprazole. Studies reporting clinical improvement suggested that this may require a relatively long time (~11 weeks), while studies that found symptom worsening observed this happening in a shorter timeframe (~3 weeks). Patients with longer illness duration who received add-on aripiprazole on ongoing FDA monotherapy may be at greater risk for symptomatologic worsening. Especially in these cases, close clinical monitoring is therefore recommended during the first few weeks of combined treatment. These indications may be beneficial to psychiatrists who consider using this treatment strategy. Well-powered randomized clinical trials are needed to derive more solid clinical recommendations.
|
|---|---|
| Authors | Matteo Lippi, Giuseppe Fanelli, Chiara Fabbri, Diana De Ronchi, Alessandro Serretti |
| Journal | International clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 37 Issue 6 Pg. 263-275 (11 01 2022) ISSN: 1473-5857 [Electronic] England |
| PMID | 35815937 (Publication Type: Journal Article, Review) |
| Copyright | Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!